Surveillance

A 5-year look-back at the notification and management of vaccine supply shortages in Germany

Maria Auxiliadora Miranda-García¹, Marcus Hoffelner¹, Hagen Stoll¹, Dörte Ruhaltinger¹, Klaus Cichutek¹, Anette Siedler², Isabelle Bekeredjian-Ding¹
1. Paul Ehrlich Institut, Langen, Germany
2. Robert-Koch-Institut, Department for Infectious Disease Epidemiology, Berlin, Germany
Correspondence: Isabelle Bekeredjian (isabelle.bekeredjian-ding@pei.de)

Citation style for this article: Miranda-García Maria Auxiliadora, Hoffelner Marcus, Stoll Hagen, Ruhaltinger Dörte, Cichutek Klaus, Siedler Anette, Bekeredjian-Ding Isabelle. A 5-year look-back at the notification and management of vaccine supply shortages in Germany. Euro Surveill. 2022;27(17):pii=2100167. https://doi.org/10.2807/1560-7917.ES.2022.27.17.2100167

Article submitted on 06 Feb 2021 / accepted on 09 Jan 2022 / published on 28 Apr 2022

Background: Unavailability of vaccines endangers the overall goal to protect individuals and whole populations against infections. Methods: The German notification system includes the publication of vaccine supply shortages reported by marketing authorisation holders (MAH), information on the availability of alternative vaccine products, guidance for physicians providing vaccinations and an unavailability reporting tool to monitor regional distribution issues. Aim: This study provides a retrospective analysis of supply issues and measures in the context of European and global vaccine supply constraints. Results: between October 2015 and December 2020, the 250 notifications concerned all types of vaccines (54 products). Most shortages were caused by increased demand associated with immigration in Germany in 2015 and 2016, new or extended vaccine recommendations, increased awareness, or changes in global immunisation programmes. Shortages of a duration up to 30 days were mitigated using existing storage capacities. Longer shortages, triggered by high demand on a national level, were mitigated using alternative products and re-allocation; in a few cases, vaccines were imported. However, for long lasting supply shortages associated with increased global demand, often occurring in combination with manufacturing issues, few compensatory mechanisms were available. Nevertheless, only few critical incidents were identified: (i) shortage of hexavalent vaccines endangering neonatal immunisation programmes in 2015; (ii) distribution issues with influenza vaccines in 2018; and (iii) unmet demand for pneumococcal and influenza vaccines during the coronavirus disease (COVID)-19 pandemic. Conclusion: Vaccine product shortages in Germany resemble those present in neighbouring EU states and often reflect increased global demand not matched by manufacturing capacities.

Introduction

The success of immunisation programmes depends on the availability of effective and safe vaccines. Vaccine shortages can negatively affect the success of immunisation programmes and endanger populations with the lowest coverage and the highest risk for infection. Vulnerable patient groups such as pre-term infants, pregnant women, and people with chronic medical conditions (e.g., immunocompromised and elderly individuals) are often under-vaccinated [1]. Thus, access to medicines or vaccines should follow the principle of prioritisation of high-risk groups and, when availability is limited, should consider an ethical framework to ensure equity and fairness along with public health interest [2,3]. COVID-19 vaccination programmes illustrate the difficulties encountered when attempting to abide by these principles [4-7].

In the European Union (EU), market approval for vaccines is granted through the European Medicines Agency (EMA) and the European Commission; however, each Member State is responsible for the official recommendation of a vaccine in its country-specific immunisation schedule and the way it is made available (e.g., via tenders or in an open market). This condition creates some diversity across the EU in regard to demand and stockpiling [8]. In contrast to other EU countries, in Germany, all EU-licensed vaccine products can be made available through the marketing authorisation holders (MAH) and there are neither tenders nor governmental vaccine stocks. With little governmental intervention except when there are shortages, MAH and pharmaceutical wholesale traders are responsible for supply and distribution of vaccines. To date, the total amount of vaccine doses delivered to or stored at pharmacies or with physicians is not centrally monitored. Shortages occur due to disruption of delivery during manufacturing, packaging or any stage of distribution. As unavailability of vaccines could lead to a delay or even omission of vaccinations, national immunisation
programmes could be compromised, placing vulnerable populations at increased risk [1]. However, the actual impact of severe shortages is often difficult to assess. Concurrent with an increased global demand, shortages of vaccines and medicinal products have become more frequent, raising concerns of systemic market failures in a product category considered to bring only low return of investment despite complex manufacturing processes [9-14].

Vaccine supply shortages remain critical issues globally, including in most European countries [14,15]. The European Commission and EMA have addressed the threat and issued recommendations for prevention and management of shortages of important medicinal products, which was further supported by the European Council recommendation of 7 December 2018 on strengthened cooperation against vaccine-preventable diseases (2018/C 466/01) [15-18]. There are some important tools for managing and ideally preventing vaccine shortages. In the immediate situation, alternative products and solutions should be made available to those potentially affected by shortages. As in many parts of the world, many European countries have initiated communication practices that inform the public and professionals on vaccine shortages on the national level (Supplement S1, Notification systems in the EU) and [19]. However, data collection and the definition of shortages have not been harmonised. In 2019, the single point of contact (SPOC) was adopted by Human Medicines Agencies (HMA) and the EMA Management Board. The SPOC system intends to improve the collaboration on shortages and availability across the EU regulatory network [20]. The SPOC should contribute to better detection, notification, prevention, management and communication on availability issues [21].

Despite all these efforts, few data have been published on the frequency and impact of vaccine shortages in the EU. Furthermore, the actual impact of shortages...
and mitigation measures on specific vaccine-preventable diseases remain ill-defined. Here, we explain the current German reporting system for vaccine shortages and the integrated guidance, which was established to mitigate the consequences of the unavailability. This 5-year retrospective analysis of vaccine shortages from October 2015 to December 2020 provides insight into the major causes and dynamics of these shortages as well as the utility of the system.

**Methods**

**Notification and management of vaccine shortages in Germany**

In 2015, we established a system for public reporting of vaccine supply shortages in Germany. The system is based on MAH providing voluntary information on upcoming supply shortages and the estimated duration of cessation of supply. Notably, the system provides information on the delivery capacity of MAH, not market supply. Supply shortage is defined as an expected interruption of more than 2 weeks of supply at the level of the manufacturer or if an unexpectedly high demand cannot be met. Incoming reports are categorised based on the risk for supply constraints on the market and impairment of the vaccination schedule (Supplement S2, Shortage classification). These reports are published within 24 hours and updated upon notification of the MAH. The results are presented to the MAH, and the system revised yearly.

One unique feature of the system is that it offers solutions to mitigate the consequences of supply shortages. These include listing of alternative vaccine products with the same indication or other packaging sizes. Availability of alternative vaccine products is confirmed by the respective MAH. If alternatives are not available or indications differ between the product in shortage and that being available, the Standing Committee on Vaccination (STIKO) issues guidance for vaccinating physicians. Specifically, STIKO guides physicians on specific risk groups, postpone booster doses, or use vaccine products with similar or extended indications when feasible.

To monitor regional distribution issues, we introduced an electronic form where unavailability of vaccine products (not listed as shortages) is reported together with the pharmacies or wholesalers are contacted (www.pei.de/liefersengpaesse-verbrauchermeldung). Reports are reviewed regularly to detect impending shortages on the regional and national level.

**Comparison with other EU countries**

Websites providing information of supply shortages were systematically searched for by EU country (Supplement S1). The shortages and their severity were verified by comparison of supply shortages for vaccine products published in other EU countries. These were searched for and collected via systematic screening of lists and downloads available on the websites of the responsible government organizations and are listed under ‘EU-based comparison of shortage notifications’.

**Results**

**Classification and duration of reported shortages**

Altogether, 250 supply shortages were reported from October 2015 to December 2020 for 54 vaccine products. These included 124 (49.6%) shortages of certain packaging sizes (category 1, Supplement S2) and 126 (50.4%) product shortages in the other categories (50 category 2 and 76 category 3). The overall frequency of product shortages fluctuated over the years (Figure, panel A): 2015 (only the 4th quarter) (n = 14), 2016 (n = 28), 2017 (n = 29), 2018 (n = 31), 2019 (n = 15) and 2020 (n = 9). The duration of product shortages (category 2 and 3) was on average 134.85 days ± 200 days; 20 (16%) shortages were resolved within 30 days, 60 (48%) shortages lasted between 31 and 100 days, and 46 (36%) shortages lasted more than 100 days (Figure, panel B). All types of vaccines (54 vaccine products) were in shortage once or several times (Figure, panel C). Shortages of certain vaccine types occurred repeatedly such as MMR-V vaccines (Figure, panel D).

---

**Table 1**

| Vaccine type | 2016 | 2017 | 2018 | 2019 | 2020 | Total (n = 40) |
|-------------|------|------|------|------|------|----------------|
| Hepatitis A | 1 | 3 | 2 | 0 | 0 | 6 |
| Hepatitis B | 0 | 2 | 3 | 1 | 0 | 6 |
| MMR-V | 0 | 0 | 1 | 0 | 1 | 2 |
| HPV | 0 | 0 | 0 | 0 | 1 | 1 |
| Td | 0 | 1 | 2 | 0 | 0 | 3 |
| Tetanus | 0 | 2 | 2 | 0 | 0 | 4 |
| Typhus | 0 | 1 | 0 | 0 | 0 | 1 |
| DTaP | 1 | 0 | 0 | 0 | 0 | 1 |
| DTaP-IPV-Hib | 1 | 0 | 0 | 0 | 0 | 1 |
| DTaP-IPV-HepB-Hib | 0 | 1 | 0 | 0 | 0 | 1 |
| Tdap-IPV | 2 | 1 | 0 | 0 | 0 | 3 |
| IPV | 1 | 2 | 0 | 0 | 0 | 3 |
| Rabies | 0 | 2 | 1 | 0 | 0 | 3 |
| Yellow fever | 1 | 0 | 0 | 0 | 1 | 1 |
| Herpes zoster | 0 | 0 | 0 | 1 | 0 | 1 |
| Meningococcus | 1 | 0 | 1 | 0 | 0 | 2 |
| Pneumococcus | 1 | 0 | 0 | 0 | 0 | 1 |

DTaP: diphtheria, tetanus, acellular pertussis; DTaP-IPV-Hib: diphtheria, tetanus, acellular pertussis, polio, haemophilus influenzae type b; DTaP-IPV-HepB-Hib: diphtheria, tetanus, acellular pertussis, polio, hepatitis B, haemophilus influenzae type b; HPV: human papillomavirus; IPV: polio; MMR-V: measles, mumps, rubella, varicella; Td: tetanus, diphtheria; Tdap: tetanus, diphtheria, acellular pertussis; Tdap-IPV: tetanus, diphtheria, acellular pertussis, polio.
Notably, in 2018, a 38% reduction in shortages for category 3 products was accompanied by an increase in category 2 products; twice as many shortages were notified for category 2 in 2018 than in 2017 (Figure, panel A). In 2019, there was a marked reduction of category 3 shortages; however, the few products reported belonged to those with a long shortage duration. The vaccines subject to shortages more than 100 days between 2016 and 2020 are listed in Table 1. Many of these shortages were labelled with ‘limited availability’ on the PEI shortage website because demand exceeded regularly provided supply. Causes of shortages reported by the MAH are summarised in Table 2. Of note, in Germany, MAH are responsible to forecast demand using market surveys, epidemiological data and subscriptions from previous years. Furthermore, as access to vaccination occurs via physician contacts, patients requiring regular medical care have easier access.

### Shortages trigger supply constraints of other packaging sizes and products

Of the 54 vaccines in shortage, 23 products were only reported once and remained in the category they were first assigned. Five category 1 products became category 2 products and six category 2 products became category 3 products. Thus, cessation of supply of a certain packaging size can precede a product shortage, and a shortage can trigger shortage of alternative products. Notably, resolution of shortages also permitted re-evaluation and downscaling of the shortage category from category 3 to category 2 for seven products. Other changes in category, such as from category 3 to category 1, were less frequently observed.

### Availability reporting

From Q4/2018 to Q4/2020, 8,447 reports were registered. The main users of this reporting tool were pharmacists (56%, n=4,771), physicians (17%, n=1,423), and private individuals (27%, n=2,253). Of the private individuals, 29% (n=1,257) visited one pharmacy, 16% (n=722) visited two pharmacies, and 55% (n=2,442) visited three or more pharmacies. The majority of reports were related to influenza vaccines in the 2018/19 (n=2,650) and the 2020/21 (n=5,772) influenza seasons; by contrast, only 11 reports were submitted in the 2019/20 influenza season. In addition, human papilloma virus and herpes zoster vaccine shortages were reported in 2019/20, and a pneumococcal polysaccharide vaccine shortage was reported in 2020 due to the higher demand during the coronavirus disease (COVID-19) pandemic. Notably, these notifications reflected unavailability of certain packaging sizes or known supply constraints, which were classified as ‘limited availability’ because of demand exceeding production capacity.

### Critical vaccine shortages and mitigations

Cessation of delivery at the MAH does not necessarily reflect the market situation. Thus, every shortage requires specific evaluation and measures. Only on three occasions did the German Ministry of Health declare a critical shortage (German medicines legislation, AMG §79 [5]). This legal measure facilitates the import of medicines to prevent or mitigate shortages and was used in three circumstances.

In 2016, there was a temporal shortage of hexavalent vaccines for primary immunisation of neonates (DTP/Polio/Hib/HepB) following a quality issue that delayed production. It was effectively bridged by increasing the market share of an alternative product, which included import of vaccine doses enabled by this legal measure. During the 2018/19 influenza season, regional distribution problems of influenza vaccines were mitigated by enabling exchange of vaccine doses among physicians and the import of influenza vaccine doses. Consequently, unavailability reports dropped from 2,383 in November 2018 to 44 in January 2019. Notably, in 2020, reports confirmed a high demand for influenza vaccines, but no critical shortage situation was declared because supply issues were affecting many other European countries and import and reallocation were deemed inappropriate measures as they would endanger supply in other regions.

The COVID-19 pandemic was an important stress test for healthcare systems and medicine supply chains. In Germany, crisis-mediated risk awareness drove the demand for vaccines for other respiratory pathogens (e.g., influenza virus and pneumococcus). This demand was in line with the experts’ opinion that the elderly population needed protection from respiratory pathogens [6], but this demand overstrained the market offer. By contrast, worldwide vaccination programmes suffered from lockdown measures and prioritisation

---

**Table 2**

| Shortages causes                               | 2017 | 2018 | 2019 | 2020 | Total | %   |
|------------------------------------------------|------|------|------|------|-------|-----|
| Manufacturing issues                           | 3    | 16   | 3    | 1    | 23    | 28.4|
| Increased demand                               | 15   | 13   | 10   | 5    | 43    | 53.0|
| Both items reported (Manufacturing problems + increase in demand) | 5    | 1    | 1    | 0    | 7     | 8.7 |
| Other issues                                   | 6    | 1    | 1    | 0    | 8     | 9.9 |
| Total                                          | 29   | 31   | 15   | 6    | 81    | 100 |

* Category 2: product shortages with availability of alternative products; category 3: product shortages without availability of alternative products (Supplement S2).
## Table 3A
Comparative analysis of vaccine supply shortages in Germany, France, Switzerland, and Austria, 2016–2020

| Year | Vaccine products in shortage | Germany\(^a\) | France\(^b\) | Switzerland\(^c\) | Austria\(^d\) |
|------|-----------------------------|--------------|-------------|----------------|--------------|
| 2020 | Pneumococcus, MMR-V, Herpes zoster | BCG, Cholera, DTaP-IPV-Hib, Hepatitis A, MMR\(^e\), Pneumococcal polysaccharide vaccine\(^e\) | Pneumococcal polysaccharide vaccine\(^e\), Polio | Hepatitis B, MMR-V, Pneumococcal polysaccharide vaccine\(^e\) |
| 2019 | Hepatitis A, Hepatitis B, Herpes zoster, MMR-V, Cholera, Japanese encephalitis | Act-Hib, BCG, C-type meningitis, Hepatitis B, HPV, MMR\(^e\), Rabies, TBEV, Yellow fever | Cholera, Polio, Rabies | Hepatitis B, |
| 2018 | Hepatitis A, Hepatitis B, Td, MMR-V, Meningococcus, Rabies | MMR\(^e\), pneumococcal polysaccharide vaccine, Tetanus | Hepatitis B, Polio | C-type meningitis, Hepatitis B, MMR-V, |
| 2017 | Tdap-IPV, Hepatitis A, Hepatitis A + Hepatitis B, Hepatitis A + Typhus, Hepatitis B, Typhus, DTaP-IPV-HepB-Hib, DTaP-IPV-Hib, DTaP | DTaP, Hepatitis A and B\(^e\), Polio\(^e\) | Polio | Hepatitis B\(^e\) |

Act-Hib: haemophilus b conjugate; BCG: bacillus Calmette–Guérin; DT: diphtheria, tetanus; DTaP: diphtheria, tetanus, acellular pertussis; DTaP-IPV-Hib: diphtheria, tetanus, acellular pertussis, polio, haemophilus influenzae type b; DTaP-IPV-HepB-Hib: diphtheria, tetanus, acellular pertussis, polio, hepatitis B, haemophilus influenzae type b; HPV: human papillomavirus; IPV: polio; MMR-V: measles, mumps, rubella, varicella; TBEV: tick-borne encephalitis; Td: tetanus, diphtheria; Tda: tetanus, diphtheria, acellular pertussis; Td-iPV: tetanus, diphtheria, polio; Tdap-IPV: tetanus, diphtheria, acellular pertussis, polio.

\(^a\) This study.
\(^b\) https://ansm.sante.fr/S-informer/Informations-de-securite-Ruptures-de-stock-des-medicaments.
\(^c\) https://www.bwl.admin.ch/bwl/de/home/themen/heilmittel/meldestelle/aktuelle_versorgungsstoerungen.html.
\(^d\) https://medicineshortage.basg.gv.at/vertriebeinschraenkungen/faces/adf.task-flow;sessionid=ycOgibZMWj eMKbztQtSc8w2koQ1i-J9Vyy2ZzhQ-fZvQ8l5zKUM1940367347?_id=main-btf&_document=WEB-INF/main-btf. xml&_afrLoop=1977832160706928&_afrWindowMode=0&_afrWindowId=null.
\(^e\) Shared supply shortages.
As expected, limited production capacity for COVID-19 vaccines led to shortages, prioritisation of risk groups for primary and booster vaccinations, especially elderly people [5,23], and inequity in global distribution [4,24].

Facing an unexpectedly high demand during the COVID-19 pandemic, the Ministry of Health declared a critical shortage for pneumococcal vaccines, which allowed for the import of vaccines with a label in another language than German. However, the measure was less effective than in other occasions because there was no suitable alternative product for the unconjugated pneumococcal polysaccharide vaccine and only limited amounts of vaccine were available for re-allocation to Germany as other countries, including EU countries, were experiencing similar supply issues. Unavailability of unconjugated pneumococcal polysaccharide vaccine still resulted in additional supply shortages of conjugated pneumococcal polysaccharide vaccines despite divergent recommended indications.

### EU-based comparison of shortage notifications

A comparison of vaccine shortage reporting systems in France and the German-speaking countries revealed differences: the French system distinguishes cessation of supply, supply shortage, tension in supply, and resolved shortage; the Austrian system’s website provides supply shortages and limited availability; and the Swiss system’s list is limited to supply shortages. However, all three countries had specific shortages that resembled the shortages experienced in Germany, with exception of BCG and Act-HiB vaccines, which are not marketed in Germany, Austria, or Switzerland (Table 3).

### Discussion

The dual reporting system analysed in this study offers transparency in regard to current, upcoming, and past shortages and combines this with vaccine-specific shortage management based on information on availability of alternative products and specific guidance in line with the World Health Organization’s (WHO) recommendations [14]. Guidance and immediate solutions are keys to mitigating the risks associated with shortages, but not all national reporting tools provide these.
was - so far - not forced to change the immunization
reason why Germany, in contrast to other EU countries,
through competing vaccine products. This may be the
German market is that shortages can be compensated
ability of alternative products. One advantage of the
have tenders, which secure supply but restrict avail -
ity is often not viable. Furthermore, many countries
ct shortages exceeded 30 days, including all DTaP
products. However, in 2015/16, 35 of the vaccine prod-
uct shortages exceeded 30 days, including all DTaP
vaccine shortages. These shortages made it neces-
sary to find alternative vaccine products, delay booster
vaccinations, and prioritise risk groups. The need for
alternative products for primary immunisation beyond
the age of 5 years resulted in off-label use because of
non-congruent age indications. Subsequent regulatory
approval of aligned age indications for several DTaP
vaccines facilitated interchangeable use [25]. Delaying
booster vaccinations risked that vaccinees would not
be able to catch up with their vaccination schedules.
Behavioural studies involving physicians facing vaccine
supply issues could help identify the measures and
communication concepts most effective at preventing
delays in vaccine schedules [26,27]. Luckily, paediatric
and adolescent vaccination rates in Germany remained
stable [28].

Promoting vaccination requires access to vaccines
and recognising the difficulties in securing supply and
dealing with unprecedented unavailability of vaccines.
As reported to GAVI, 65 countries reported at least
one national-level stock-out in 2015, and 73 countries
reported 131 stock-out events in 2016. Whereas stock-
outs were mostly attributed to funding delays [29], in
China, limited production, limited governmental batch
release testing capacities, and delays in procurement
were also considered important obstacles [30]. To
avoid constraints and delays, the EU system builds on
release of vaccines by Official Member State Control
Laboratories (OMCL) [31] and parallel testing by OMCL
and manufacturers. Release of vaccines is mutually
recognised by other Member States, which reduces
regulatory hurdles, and increases batch release capac-
ities (EU Directive for Human Medicines, 2001/83/EC).

Stock-outs for DTP, polio, and BCG-containing vac-
cines were predominantly reported to GAVI in 2015/16
[32,33], in China in 2017/18 [30] and across the EU [19].
In Germany, the most frequently reported products in
shortage were pertussis and polio-containing poly-
valent vaccines (n=30). Shortages of DTaP vaccines
in 2015/16 reflected the migration crisis, increased
global demand (i.e., switch from whole cell DTwP to
acellular DTaP), and delays associated with upscaling
of production capacities [13]. Prolonged supply con-
straints for polio-containing vaccines in 2016/17 (Table
1) were evoked by the switch from oral (OPV) to inac-
tivated polio vaccines (IPV) in many global regions
[34]. The global IPV demand more than doubled from
2013 to 2016, a stress that required upscaling of global
production capacities and resulted in supply con-
straints, delaying the switch in many regions beyond
2017 [34-36]. In Germany, physicians were urged not
to booster travellers and travellers were urged not to
seek boosters.

In agreement with previous reports [2,14,20,37], the
most frequent cause for shortages was increased
demand on either the national or global level, followed
by issues related to manufacturing. Sometimes these
were interconnected (Table 2). Manufacturing issues
have a strong impact on the availability of vaccines
because the same bulk materials are used in the for-
mulation of many vaccine combinations; therefore, the
unavailability of a single component results in short-
ages of all final products. Additionally, long-lasting
production cycles do not allow short-term compensa-
tory activities, and changes such as upscaling of manu-
facturing can pose a risk for continuity of supply.

From 2001 to 2015, the United States (US) Federal Drug
Administration (FDA) reported shortages mainly for
viral vaccines (58%); in addition to hepatitis A and B, these included rabies and varicella virus-containing vaccines [38]. In Germany, we experienced prolonged periods of shortages of hepatitis A and B vaccines from 2017 to 2019 (Figure, panel C). Existing supply constraints driven by increased global demand were aggravated by large outbreaks of hepatitis A in the US and the United Kingdom (UK) [39,40]. Reallocation of vaccines to affected regions [39] and coincident manufacturing issues with HBsAg-containing vaccines [40-42] triggered supply shortages [25]. By contrast, rabies vaccine shortages (2016 [1], 2017 [4], 2018 [1]) were mitigated with alternative products and emergency stocks for post-exposure prophylaxis. However, a 4-month cessation of delivery of yellow fever vaccine in 2016 could not be avoided [43].

Altogether, our data indicate that the current German system for shortage notifications provides transparency and supports short-term mitigation measures to resolve supply issues. Nevertheless, it cannot revert the root causes nor protect from global increases in demand that need to be met by increased manufacturing capacity.

In 2018, more than 40,000 measles infections and 37 associated deaths [44] increased the demand for MMR-V vaccines in the EU. This coincided with manufacturing issues announced in late 2017, which were responsible for long-term unavailability of the quadrivalent vaccine from one manufacturer. The simultaneity of these events resulted in supply shortages of MMR-V vaccines in several EU countries (Table 3 and Figure, panel D). Moreover, full coverage required administration of trivalent MMR plus monovalent varicella vaccines, which endangered acceptance [45].

Many shortages occurred when new or expanded recommendations or regulations were issued. In 2018, supply issues for influenza vaccines were reported in both Germany and the UK [46]. They were attributable to changes in the UK immunisation programme and the German reimbursement policies. The revision of the STIKO recommendations for pneumococcal vaccination in 2016 triggered increased public awareness and demand for unconjugated pneumococcal polysaccharide vaccines in 2016/17. After the STIKO recommendation of HPV vaccination for boys in 2018 and the introduction of (gender-neutral) HPV vaccination in other countries, Germany experienced supply constraints with repeated stock-outs of individual packaging sizes. The WHO responded to global supply constraints by asking countries to withhold vaccination for boys [47]. Similarly, in 2019, there were shortages of herpes zoster vaccines (n=8) because the manufacturer could not meet the demand triggered by the recommendation of the subunit vaccine for individuals >60 years of age. These data underscore that new or extended vaccination programmes can be thwarted by insufficient production capacities. Furthermore, regional differences in regulatory requirements and duration of approval of changes in chemistry, manufacturing and controls (CMC) can create important logistical hurdles [12,13,37] and delay or even prevent reallocation of vaccines to regions with clinical need.

The examples provided highlight that supply shortages endanger public health goals such as elimination of polioviruses, measles and hepatitis B [36,48]. The complexity and duration of manufacturing limits short-term mitigation measures to re-allocation from existing vaccine stocks provided that batches are prepared according to current regional regulatory requirements [12,13]. Re-allocation measures can achieve transient improvement of regional supply (e.g., import of hexavalent vaccines for neonates in 2015 or the influenza vaccine in 2018). However, re-allocation measures remain ineffective in EU-wide shortages triggered by unexpectedly high demand (e.g., MMR-V vaccines in 2018 and influenza vaccines in the 2020/21), or in global supply constraints (e.g., polio and hepatitis A/B vaccines). Therefore, prevention of shortages requires (i) international collaboration to improve demand forecasting and distribution practices, (ii) international harmonisation of regulatory requirements to facilitate re-distribution, and (iii) new technological concepts to stabilise production processes and upscaling to keep pace with global demand [12-14,37,49].

Conclusions

Reporting of vaccine supply shortages should include reliable information on availability of alternative products and specific guidance for vaccinating healthcare professionals. Management of vaccine supply shortages needs to be tailored to account for national peculiarities and regional needs. Global mismatch of demand and production capacities limits the effectiveness of both immunisation programmes and regional measures for mitigation of vaccine supply shortages.

Acknowledgements

This study was funded by the German Ministry of Health COVID-19 funding to IBD. We thank all stakeholders and individuals involved for their support and efforts in establishing and maintaining the vaccine supply shortage notification platform. We further thank Dr Volker Öppling, PEI, Langen for critical reading of the manuscript.

Conflict of interest

None declared.

Authors’ contributions

All authors have contributed to the establishment of the notification system. MMG and IBD designed the study. MMG, MH, DR and HS were responsible for data collection and analyses. MMG, KC, AS and IBD were responsible for interpretation of the data and preparation of the manuscript.
Ethical statement

This study includes no animal experiments, clinical or personal data that require approval by an ethics board.

References

1. Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023-34. https://doi.org/10.1016/S0140-6736(21)00368-8 PMID: 33587887

2. Iyengar S, Hedman L, Forte G, Hill S. Medicine shortages: a public health tools. Expert Rev Vaccines. 2016;15(12):1575-84. https://doi.org/10.1080/14760584.2016.1205492 PMID: 27345296

3. Gibson JL, Bean S, Chidwick P, Godkin D, Sibbald RW, Wagner AM, et al. Understanding vaccine-preventable diseases (2018/C 466/01). Brussels: The Council of the European Union; 7 Dec 2018. Available from: https://www.eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:12018DC0466

4. Wouters OJ, Shadle P, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Ethical framework for resource allocation during a drug supply shortage. Healthc Q. 2012;15(3):26-35. https://doi.org/10.1097/HCQ.2012.09.0062 PMID: 22986563

5. Delnelyci EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400-7. https://doi.org/10.1080/21645515.2020.1804776 PMID: 32845739

6. World Health Organization Regional Office for Europe (WHO/Europe). The organization and delivery of vaccination services in the European Union (2018). Copenhagen: WHO/Europe; 2018. Available from: https://www.euro.who.int/en/publications/abstracts/the-organization-and-delivery-of-vaccination-services-in-the-european-union-2018

7. U.S. Food and Drug Administration. Drug Shortages: Root Causes and Potential Solutions; 2019. Washington: U.S. Food and Drug Administration; Oct 2019. Available from: https://www.fda.gov/drs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions

8. Danzon PM, Pereira NS, Tejwani SS. Vaccine supply: a cross-national perspective. Health Aff (Millwood). 2005;24(3):706-17. https://doi.org/10.1377/hlthaff.24.3.706 PMID: 15886165

9. Ridley DB, Bei X, Liebman EB. No Shot: US Vaccine Prices And Access to COVID-19-Impfempfehlung. [Recommendation of the Standing Committee on Vaccination on the 12th revision of the COVID-19 vaccine recommendation]. Berlin: Robert Koch Institute; 18 Oct 2021. German.

10. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205-11. https://doi.org/10.1038/s41591-020-01042-w PMID: 33662293

11. Miranda-Garcia MA, Götz KB, Ruhaltinger D, Cichutek K, Bekeredjian-Ding I. (Vaccine Supply Shortages: Insight into Numbers and Background). Lieferrungen von Impfstoffen: Einblick in Zahlen und Hintergründe. Btsch Arztebl. 2017;114(17):A-84-8.  https://doi.org/10.1080/21645515.2020.1787065 PMID: 24788111

12. Rieck T, Feig M, Wichmann O, Siedler A. Impfquoten von Kinderimpfzwecken in Deutschland – aktuelle Ergebnisse aus der RKI-Impfungsberichte. (Vaccine Rates in Pediatric Vaccinations in Germany - Recent Results from the RKI Vaccination Surveilance). Berlin: Robert Kock Institute; 6 Aug 2020. German.

13. Forster AS, Rockliffe L, Chorley AJ, Marlow LAV, Bedford H, Smith SG, et al. A qualitative systematic review of factors influencing parents’ vaccination decision-making in the United Kingdom. JSMN Popul Health. 2016;2:603-12. https://doi.org/10.1080/21645515.2016.10.005 PMID: 28018959

14. Lydon P, Schreiber B, Gasca A, Dumolard L, Ufer D, Senouchi K. Vaccine stockouts around the world: Are essential vaccines always available when needed? Vaccine. 2017;35(17):2212-6. https://doi.org/10.1016/j.vaccine.2016.12.071 PMID: 28194919

15. Li Z, Xu J, Xu J, Tan H, Zhang C. Current situation, causes, and countermeasures to NIP vaccine shortages in Guangzhou, China. Hum Vaccin Immunother. 2020;16(1):76-9. https://doi.org/10.1080/21645515.2019.1644883 PMID: 31403888

16. Kretzschmar E, Muckenfuss H, Pfleiderer M. Official batch control of influenza vaccines: Is it still useful? Vaccine. 2018;36(7):2364-70. https://doi.org/10.1016/j.vaccine.2018.02.076 PMID: 29586039

17. World Health Organization (WHO). Global Vaccine Action Plan. Monitoring, Evaluation and Accountability: Secretariat Annual Report. Geneva: WHO; 2017. Available from: https://www.who.int/immunizat/index.html

18. World Health Organization (WHO). Global Vaccine Action Plan. Monitoring, Evaluation & Accountability: Secretariat Annual Report. Geneva: WHO; 2016.

19. Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton J, et al. Accelerated Global Introductions of Inactivated Poliovirus Vaccine. Int J Pharm. 2020;579:119171. https://doi.org/10.1016/j.ijpharm.2020.119171 PMID: 32092450

20. Musazzi UM, Di Giorgio D, Minghetti P. New regulatory strategies to manage medicines shortages in Europe. Int J Pharm. 2020;579:119171. https://doi.org/10.1016/j.ijpharm.2020.119171 PMID: 32092450

21. Filia A, Rota MC, Grossi A, Martinelli D, Prato R, Rezza G. Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination. Vaccine. 1998-05. https://doi.org/10.1016/j.vaccine.2022.02.041 PMID: 35950211

22. Bogaert P, Bochenek T, Prokop A, Pilc A. A Qualitative Approach to a Better Understanding of the Problems Underlying Drug Shortages, as Viewed from Belgian, French and the EU’s Perspective. PLoS ONE. 2015;10(10):e0125691. https://doi.org/10.1371/journal. pone.0125691 PMID: 25942432

23. European Medicines Agency (EMA). Annual Report 2019: The European Medicines Agency’s contribution to help ensure the supply of medicines, vaccines and health in 2019: Amsterdam; EMA: 2020. Available from: https://www.ema.europa.eu/en/annual-report-2019/index.html

24. Ali I. Impact of COVID-19 on vaccination programs: adverse or positive? Hum Vaccin Immunother. 2020;16(11):2594-600. https://doi.org/10.1080/21645515.2020.1787065 PMID: 32961081
Introduction in Support of the Polio Endgame. J Infect Dis. 2017;216(suppl_1):S15-23. https://doi.org/10.1093/infdis/jix185 PMID: 28836203

37. Vaccines Europe. From vaccines shortages to sustainable vaccine supply: Vaccines Europe Position. Brussels: Vaccines Europe. 29 Apr 2016. Available from: https://www.vaccineseurope.eu/

38. Ziesenitz VC, Mazer-Amirshahi M, Zocchi MS, Fox ER, May LSUS. U.S. vaccine and immune globulin product shortages, 2001-15. Am J Health Syst Pharm. 2017;74(22):1879-86. https://doi.org/10.2146/ajhp170066 PMID: 28970246

39. Foster M, Ramachandran S, Myatt K, Donovan D, Bohm S, Fiedler J, et al. Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(43):1208-10. https://doi.org/10.15585/mmwr.mm674333 PMID: 30383739

40. Mandal S, Edelstein M, Ramsay M. Public health leadership in the UK’s response to hepatitis A and hepatitis B vaccine shortages. Vaccine. 2020;38(19):3515-6. https://doi.org/10.1016/j.vaccine.2020.01.010 PMID: 31948821

41. Matthews PC, Barnes E. Hepatitis B vaccine shortage: another symptom of chronic neglect? BMJ. 2017;359:j4686. PMID 29051262.

42. Collier R. No end in sight for adult hepatitis B vaccine shortage. CMAJ. 2010;182(12):E580. https://doi.org/10.1503/cmaj.109-3324 PMID: 20682737

43. Miranda-Garcia M, Chichutek K, Bekeredjian-Ding I. Wie lange bleibt der Kühlschrank leer?: Das Paul-Ehrlich-Institut analysierte die Lieferengpässe bei Reiseimpfstoffen. Dtsch Apoth Ztg. 2017; (51):24-5.

44. Kmietowicz Z. Measles: Europe sees record number of cases and 37 deaths so far this year. BMJ. 2018;362k3596. PMID 30126938

45. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9(8):1763-73. https://doi.org/10.4161/hv.24657 PMID: 23584253

46. Torjesen I. Flu vaccine shortages: NHS England must improve planning to avoid a repeat of this year's delays. BMJ. 2018;363:k3345 PMID 30373915.

47. Arie S. HPV: WHO calls for countries to suspend vaccination of boys. BMJ. 2019;367k6765. PMID 31792022.

48. Doherty M, Buchy P, Standaert B, Giaquinto C, Prado-Cohrs D. Vaccine impact: Benefits for human health. Vaccine. 2016;34(52):6707-14. https://doi.org/10.1016/j.vaccine.2016.10.025 PMID: 27773475

49. Ndaya-Oloo P, Pitisuttithum P, Tornieporth NG, Desgrandchamps D, Munoz FM, Kochhar S, et al. Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. J Clin Pharmacol. 2018;58 Suppl 10:S123-S139. PMID 30248195.

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.